Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/12660
Título : Ex-vivo trans-corneal and trans-scleral diffusion studies with ocular formulations of glutathione as an antioxidant treatment for ocular diseases
Autor : Sebastián Morelló, María.
Alambiaga Caravaca, Adrián Miguel.
Calatayud Pascual, María Aracely.
Rodilla Alamá, Vicente.
Balaguer Fernández, Cristina.
Miranda Sanz, María.
López Castellano, Alicia Cristina.
Materias: Glutatión - Uso terapéutico.Glutathione - Therapeutic use.Ojos - Enfermedades - Tratamiento.Antioxidants - Therapuetic use.Oxidative stress - Treatment.Antioxidantes - Uso terapéutico.Estrés oxidativo - Tratamiento.Eye - Diseases - Treatment.
Fecha de publicación : 10-sep-2020
Editorial : MDPI.
Citación : Sebastián-Morelló, M., Alambiaga-Caravaca, A.M., Calatayud-Pascual, M.A., Rodilla, V., Balaguer-Fernández, C., Miranda, M. et al. (2020). Ex-vivo trans-corneal and trans-scleral diffusion studies with ocular formulations of Glutathione as an antioxidant treatment for ocular diseases. Pharmaceutics, vol. 12, i. 9 (10 sep.), art. 861. DOI: https://doi.org/10.3390/pharmaceutics12090861
Resumen : Exposure to sunlight and contact with atmospheric oxygen makes the eye particularly susceptible to oxidative stress, which can potentially produce cellular damage. In physiological conditions, there are several antioxidant defense mechanisms within the eye. Glutathione (GSH) is the most important antioxidant in the eye; GSH deficit has been linked to several ocular pathologies. The aim of this study was to explore the potential for newly developed formulations allowing controlled delivery of antioxidants such as GSH and vitamin C (Vit C) directly to the eye. We have investigated the stability of antioxidants in aqueous solution and assessed ex-vivo the di usion of GSH through two ocular membranes, namely cornea and sclera, either in solution or included in a semisolid insert. We have also carried out the hen’s egg-chlorioallantoic membrane test (HET-CAM) to evaluate the ocular irritancy of the di erent antioxidant solutions. Our results showed that GSH is stable for up to 30 days at 4 C in darkness and it is not an irritant to the eye. The di usion studies revealed that the manufactured formulation, a semisolid insert containing GSH, could deliver this tripeptide directly to the eye in a sustained manner.
Descripción : Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/1999-4923/12/9/861
Este artículo pertenece al número especial "Controlled delivery formulations".
URI : http://hdl.handle.net/10637/12660
Derechos: http://creativecommons.org/licenses/by/4.0/deed.es
ISSN : 1660-4601 (Electrónico).
Aparece en las colecciones: Dpto. Farmacia

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Ex-vivo_Sebastian_PHARMACEUTICS_2020.pdf2,15 MBAdobe PDFVisualizar/Abrir

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.